News
-
Agomab Therapeutics has announced interim results from a Phase 1 study of AGMB-447 inhaled ALK5 inhibitor that was initiated in 2023. The data from the SAD/MAD portion of the study in 108 healthy participants found… Read more . . .
-
Krystal Biotech has announced results from the highest dose cohort of its Phase 1 CORAL-1 trial of KB407 gene therapy that confirm CFTR expression in 6 of 7 cystic fibrosis patients who received 4 administrations… Read more . . .
-
Pulmocide has announced the termination of the Opera-T Phase 3 study of opelconazole inhalation suspension in patients with invasive pulmonary aspergillosis. According to the company, an interim analysis found that patients receiving opelconazole had poorer… Read more . . .
-
Florida-based inhaled drug developer Transpire Bio has announced the initiation of a Phase 1 trial of a synthetic inhaled cannabidiol formulation, which the company is developing for Parkinson’s disease psychosis and for other central nervous… Read more . . .
-
Milestone Pharmaceuticals announced that the European Medicines Agency has accepted the company’s marketing application for its etripamil nasal spray for the treatment of paroxysmal supraventricular tachycardia (PSVT), with a decision expected in early 2027. If approved, the… Read more . . .
-
GH Research announced that the FDA has lifted a clinical hold on the company’s IND for GH001 inhaled mebufotenin (5-MeO-DMT) for the treatment of treatment-resistant depression and that initiation of a Phase 3 trial is… Read more . . .
-
According to SoftOx Solutions, the Danish Medicines Agency has approved the company’s application for a Phase 2a trial of SoftOx hypochlorous acid inhalation solution in healthy volunteers and in patients with cystic fibrosis. SoftOx announced… Read more . . .
-
The Chinese National Medical Products Administration (NMPA) has approved a 2 mg dose of ARS Pharmaceuticals’s neffy epinephrine nasal spray for the treatment of anaphylaxis in patients who weigh 30 kg or more, the company said.… Read more . . .
-
Cipla has launched Afrezza inhaled dry powder insulin for the treatment of diabetes in adult patients in India, the company said. Cipla acquired the rights to market Afrezza in India from MannKind Corporation in 2018,… Read more . . .
-
Once again, the annual Drug Delivery to the Lung (DDL) conference drew approximately 1,000 inhaled and nasal drug delivery experts to the Edinburgh International Conference Centre, with an additional 100 delegates attending online. With a… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
May 10-May 14: RDD 2026, Phoenix, AZ, USA
May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA
May 17-May 20: ATS International Conference 2026, Orlando, FL, USA
June 10: SMI.London 2026, London, UK
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan